Eli Lilly (NYSE:LLY) announced earnings recently, and the results weren't good. Revenue fell 16%, and net income dropped an eye-popping 53%. Lilly is in a transition period as generic competition eats away at well-known franchises, but the company had pipeline success from Cyramza and is executing deals to bolster its overall business, including increasing Elanco to the second largest animal health player.

In this segment from Market Checkup, Motley Fool health-care analysts David Williamson and Michael Douglass take investors through some of the key numbers to know from Eli Lilly's report this quarter. David looks through several of the sales numbers for the pharmaceutical conglomerate's key products, notes one piece of good news from the report, and discusses some of the near-term challenges he sees facing the company today.

Invest in the next wave of health care innovation
The Economist compares this disruptive invention to the steam engine and the printing press. Business Insider says it's "the next trillion-dollar industry." And the technology behind is poised to set off one of the most remarkable health-care revolutions in decades. The Motley Fool's exclusive research presentation dives into this technology's true potential, and its ability to make life-changing medical solutions never thought possible. To learn how you can invest in this unbelievable new technology, click here now to see our free report.

David Williamson, Michael Douglass, and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.